Explore how a specialized ablation technique may improve treatment outcomes for patients with persistent atrial fibrillation by targeting hard-to-reach electrical pathways in the heart.
Dr. Miguel Valderrábano and his team aim to evaluate the long-term efficacy and outcomes of retrograde venous ethanol ablation in treating ventricular arrhythmias through the VENUS trial published in JAMA. The team found that retrograde coronary venous ethanol ablation (RCVEA) can be effective for radiofrequency ablation (RFA)- refractory VAs, particularly those arising in the LV summit (LVS).
Did you find this article helpful?
Thank you for your feedback.
Subscribe to our Newsletter
Please enter an email
Please enter a valid email
Related Articles